• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

正在研发的新冠疫苗，抗体是否足够？

COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?

作者信息

Hossain Md Kamal, Hassanzadeganroudsari Majid, Feehan Jack, Apostolopoulos Vasso

机构信息

Institute for Health and Sport, Victoria University, Melbourne, VIC 3011, Australia.

The Department of Medicine-Western Health, The University of Melbourne VIC, Melbourne, VIC 3021, Australia.

出版信息

Vaccines (Basel). 2021 Mar 10;9(3):241. doi: 10.3390/vaccines9030241.

DOI:10.3390/vaccines9030241
PMID:33802086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7999244/
Abstract

The COVID-19 pandemic caused by the novel coronavirus strain SARS-CoV-2 has already led to catastrophic consequences in global physical and psychological health, as well as economic recession [...].

摘要

由新型冠状病毒SARS-CoV-2引起的COVID-19大流行已经在全球身心健康以及经济衰退方面导致了灾难性后果[……]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1663/7999244/7cdc942df748/vaccines-09-00241-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1663/7999244/7cdc942df748/vaccines-09-00241-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1663/7999244/7cdc942df748/vaccines-09-00241-g001.jpg

相似文献

1
COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?正在研发的新冠疫苗，抗体是否足够？
Vaccines (Basel). 2021 Mar 10;9(3):241. doi: 10.3390/vaccines9030241.
2
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.2020 年大流行：当前 SARS-CoV-2 疫苗的开发。
Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020.
3
Could SARS-CoV-1 Vaccines in the Pipeline Have Contributed to Fighting the COVID-19 Pandemic? Lessons for the Next Coronavirus Plague.正在研发中的严重急性呼吸综合征冠状病毒1（SARS-CoV-1）疫苗是否有助于抗击新冠疫情？对下一次冠状病毒疫情的启示。
Biomedicines. 2023 Dec 27;12(1):62. doi: 10.3390/biomedicines12010062.
4
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19（Sars-Cov-2）的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
5
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）/COVID-19 及其相关疗法和疫苗的研究进展，以应对这一新兴的大流行病。
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40. doi: 10.1186/s12941-020-00384-w.
6
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.三种原型株衍生重组蛋白疫苗对 B.1.1.7、B.1.351 和 B.1.617.1 变异 SARS-CoV-2 诱导产生广谱中和抗体。
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
7
Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.SARS-CoV-2 刺突蛋白与人 ACE2 受体相互作用的蛋白质结构分析：从构象变化到新型中和抗体。
Cell Mol Life Sci. 2021 Feb;78(4):1501-1522. doi: 10.1007/s00018-020-03580-1. Epub 2020 Jul 4.
8
The novel zoonotic COVID-19 pandemic: An expected global health concern.新型人畜共患的新冠疫情：一个意料之中的全球卫生问题。
J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671.
9
Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.宿主对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的保护性免疫与 COVID-19 疫苗诱导的对 SARS-CoV-2 及其变体的免疫。
Viruses. 2022 Nov 17;14(11):2541. doi: 10.3390/v14112541.
10
Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests.SARS-CoV-2 核衣壳结合抗体的交叉反应性及其对 COVID-19 血清学检测的影响。
Viruses. 2022 Sep 14;14(9):2041. doi: 10.3390/v14092041.

引用本文的文献

1
Role of T cells in severe COVID-19 disease, protection, and long term immunity.T 细胞在严重 COVID-19 疾病、保护和长期免疫中的作用。
Immunogenetics. 2023 Jun;75(3):295-307. doi: 10.1007/s00251-023-01294-9. Epub 2023 Feb 8.
2
An extended picture fuzzy multicriteria group decision analysis with different weights: A case study of COVID-19 vaccine allocation.一种具有不同权重的扩展图像模糊多准则群体决策分析：以新冠疫苗分配为例
Socioecon Plann Sci. 2023 Feb;85:101435. doi: 10.1016/j.seps.2022.101435. Epub 2022 Sep 24.
3
Efficacy of Telemedicine and Telemonitoring in At-Home Monitoring of Patients with COVID-19.

本文引用的文献

1
Is COVID-19 the worst pandemic?新冠疫情是最严重的大流行疾病吗？
Maturitas. 2021 Jul;149:56-58. doi: 10.1016/j.maturitas.2021.02.001. Epub 2021 Feb 6.
2
Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment.Toll样受体4和血管紧张素转换酶2的双重靶向：一种治疗新型冠状病毒肺炎的建议方法。
Future Microbiol. 2021 Mar;16:205-209. doi: 10.2217/fmb-2021-0018. Epub 2021 Feb 11.
3
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
远程医疗和远程监测在新型冠状病毒肺炎患者居家监测中的疗效
J Clin Med. 2021 Jun 29;10(13):2893. doi: 10.3390/jcm10132893.
4
Nutritional Interventions for COVID-19: A Role for Carnosine?COVID-19 的营养干预：肌肽的作用？
Nutrients. 2021 Apr 26;13(5):1463. doi: 10.3390/nu13051463.
5
The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）毒株的出现。这对2019冠状病毒病（COVID-19）疫苗意味着什么？
Expert Rev Vaccines. 2021 Jun;20(6):635-638. doi: 10.1080/14760584.2021.1915140. Epub 2021 Apr 25.
基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性：俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
4
From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.从血管紧张素 II 到环肽和血管紧张素受体阻滞剂 (ARB)：ARB 在 COVID-19 治疗中的观点。
Molecules. 2021 Jan 25;26(3):618. doi: 10.3390/molecules26030618.
5
Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?SARS-CoV-2 病毒是否可以使用多种受体进入宿主细胞？
Int J Mol Sci. 2021 Jan 20;22(3):992. doi: 10.3390/ijms22030992.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
8
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
9
Covid-19: Russia approves vaccine without large scale testing or published results.新冠疫情：俄罗斯未经大规模测试或公布结果就批准了疫苗。
BMJ. 2020 Aug 13;370:m3205. doi: 10.1136/bmj.m3205.
10
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.